Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Inclusion Criteria:

• Adults aged ≥18 years.
• Diagnosed cases of type 2 diabetes mellitus.
• Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
• On stable ACE inhibitor or ARB therapy for at least 4 weeks.
• Serum potassium ≤4.8 mmol/L.
• Provided written informed consent.

Exclusion Criteria:

• Symptomatic heart failure (NYHA class II-IV).
• eGFR <25 mL/min/1.73m² or on maintenance dialysis.
• Known non-diabetic kidney disease.
• Recent major cardiovascular event (within 30 days).
• Serum potassium >4.8 mmol/L or history of severe hyperkalaemia.
• Contraindication or hypersensitivity to finerenone.
• Pregnancy or lactation.
• Any condition limiting compliance or follow-up.